TAI •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 11:13
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTAI
Market Capitalization4,397.74 mln
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.41
Borderline
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.09
Debt-free
Pre-Tax Margin
-1,658%
Severely loss-making
ROE
-25.18
Deeply negative
Business Description
Pell Bio-Med Technology, founded in 2017 and headquartered in Taipei, Taiwan, develops and sells advanced cell-based treatments designed to fight cancer and joint disease. Its core work centers on CAR-T cell therapy, a method that engineers a patient's own immune cells to target and destroy cancer, with ongoing clinical studies focused on hard-to-treat forms of blood cancer. The company also offers stem cell products to help patients recover from knee joint damage and cartilage loss.
